1. As I stated above, I shed almost 80% with a $400 + loss on a .99 p/s, therefore I have no
beef in this meatmarket any more(no cry baby here). Besides, I was busy during CC but I did call PR afterwards.
3. No need to cry on the msg board. I always go directly to the source.
3. "BTW BioMetric has nothing to do with this 510k it belongs to Abbott".
"We are in the process of shifting our focus to begin setting the stage for the anticipated U.S. market introduction of galectin-3 automated testing by our partners, Abbott and bioMerieux".
As I said before, FDA 's requested additional action from BGMD much before the qtrly report was due.
Did BGMD informed shrhldrs.? Nope and more time will be needed. At one point BGMD will get it right. Maybe solid revenues will materialize 1st Qtr 2015.
"So as I think about that in the context of your guidance, does the guidance assume no introduction of an automated test at least or at least no commercial revenues from an automated test for 2014?".
Answer: President and Chief Executive Officer
I like your future forecast enrique........let's hope for the best and see what can be delivered..... regarding promising results coming ahead!
With FDA clearance we should easily see $2-3 per share IMHO. Hopefully we also get some news on Cardioscore this quarter and take share price above $4.
Let's just hope for the most positive events to occur within the next couple of months (aka: 510 (k) response, etc.) and we will be above and beyond today's challenges.
And yes....this company could use an education in "PR / Communication 101".
That sounds very doable if they can just get 510k cleared. Like I have said before
I think that $1.40 price target will get blown away if all goes well...
Jess, once they receive the letter, they will have a minimum of 6 months and up to a year to get into compliance, compliance is any 10 days in a row over $1.00 within a year, no worries about that, as for R/S, if the 510K goes well, there will be no chance of that, remember, there are only around 36m OS, That's not much for a Bio stock.
I hate to think if they get that letter and have to do the R/S to get this back over a buck. The stock
is coming up very slow We all know how much this stock likes a positive PR so maybe we
could see something very soon.
AGAIN, hope this company has enough common sense to understand that, But I doubt they have any common sense at all when it comes to this stock. Dumb #$%$,es when it comes to shareholders
METHODS AND RESULTS:
A total of 706 patients with SCAD and a history of acute coronary syndrome (ACS) were analyzed over a follow up period of 2.2 years. The primary endpoint was the occurrence of an ischemic event (any SCA, stroke or transient ischemic attack), heart failure, or death. A clinical risk scale derived from the LIPID study significantly predicted the development of the primary endpoint, with an area under the ROC curve (Receiver Operating Characteristic) A composite score was developed by adding the scores of the LIPID and scale decile levels of MCP -1, galectin -3 and NT-proBNP. The predictive value improved with an area under the curve . A score greater than 21.5 had a sensitivity of 74% and a specificity of 61% for the development of the primary endpoint
Plasma levels of MCP-1, galectin -3 and NT-proBNP improve the ability of the LIPID clinical scale to predict the prognosis of patients with SCAD.
DEQI enters mobile poker arena by purchasing the game Actua Poker and will begin distribution of the game to all markets. Management looks top capitalize on exploding demand for mobile gaming apps in the poker niche
pump and dump scam only 5k in revs...lol
DEQI sets sights on breakout trading as management unveils three new titles to the company’s line-up. Is $2.50 a realistic trading price for the stock?
At present, there is no tool validated by scientific societies for risk stratification of patients with stable coronary artery disease (SCAD). It has been shown that plasma levels of monocyte chemoattractant protein-1 (MCP-1), galectin-3 and pro-B-type natriuretic peptide amino-terminal (NT-proBNP) have prognostic value in this population.
To analyze the prognostic value of a clinical risk scale published in Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study and determining its predictive capacity when combined with plasma levels of MCP-1, galectin-3 and NT-proBNP in patients with SCAD.
Can George Metos, former owner and founder of Sculptured Software, Inc. bring DEQI into the big leagues? Former developer of big gaming titles like Mortal Kombat brings extensive gaming development experience to DEQI
We should contact management and let them know that they should put out press releases when these studies come out. Even if they regroup two or more studies and issue one press release informing us of one or more studies done. This is important progress which should not be underestimated. It will also give more confidence to present and future shareholders.
Sentiment: Strong Buy
Usefulness of Combining Galectin-3 and BIVA Assessments in Predicting Short- and Long-Term Events in Patients Admitted for Acute Heart Failure
Conclusion - In patients admitted for AHF an early assessment of GAL3 and BIVA seems to be useful in identifying patients at high risk for death and rehospitalization at short and long term. Combining the biomarker and the device could be of great utility since they are monitoring the severity of two pathophysiological different mechanisms underlining the severity of disease: heart fibrosis and fluid overload. GAL3 per se has the strongest independent predicting value for death and rehospitalization at 30 days with a cut-off of 32.24 ng/mL. The use of combining GAL3 and BIVA assessment, at the moment of AHF patients' presentation, could support decision making and different therapeutic approach.
June 23, 2014 — BG Medicine Inc. earlier this year announced the issuance of patent 8,672,857, titled “Galectin-3 and Cardiac Resynchronization Therapy,” by the United State Patent and Trademark Office. The patent claims methods for predicting responsiveness to cardiac resynchronization therapy by the measurement of the concentration of the protein galectin-3 in blood.
Cardiac resynchronization therapy, also referred to as biventricular pacing, involves the implantation of a specialized pacemaker device to attempt to improve the heart's rhythm and alleviate symptoms associated with arrhythmia in heart failure.
"The issuance of this patent both strengthens and broadens BG Medicine's patent portfolio covering galectin-3 testing," said Paul R. Sohmer, M.D., president and CEO of BG Medicine. "We will continue to aggressively pursue the protection of our intellectual property related to galectin-3."
Had they issued a press release we would have gone up 30-50 cents, just being associated with Boston Scientific. Mind boggling how conservative they are.
Sentiment: Strong Buy